Micatrio, as a composite preparation, should be used and administered according to age and weight stratification. Special attention should be paid to safety assessment when using it for special populations. The following provides detailed instructions on standard usage and dosage, as well as adjustments for special populations, to provide standardized guidance for clinical medication.

1. Standard usage and dosage

(1) Adult dose

Take 2 tablets orally in the morning (containing 100mg of Elevacapo/50mg of Tezacofort/75mg of Ivacator) and 1 tablet orally in the evening (containing 150mg of Ivacator), with a 12 hour interval between two doses, and should be taken together with high-fat foods.

(2) Child dose

For individuals aged 2-6 years with a weight of less than 14kg: 1 packet of granules in the morning (containing 80mg of Elevacapo, 40mg of Tezacofort, and 60mg of Ivacator), and 1 packet in the evening (containing 59.5mg of Ivacator); The dosage for those weighing ≥ 14kg is the same as that of the adult component.

(3) Children aged 6-12

For those weighing less than 30kg: take 2 tablets in the morning (including 50mg of Elevacapo/25mg of Tezacofort/37.5mg of Ivacator) and 1 tablet in the evening (75mg); For those weighing ≥ 30kg, an adult dosage regimen will be used.

2. Medication for special populations

(1) Pregnancy period

There is currently insufficient data to support safety, and strict evaluation of treatment benefits and potential risks is needed. It is recommended to confirm pregnancy status before medication.

(2) Lactation period

Drug ingredients may be secreted through breast milk, and breastfeeding should be suspended during treatment until the drug is completely cleared.

(3) Children's group

The safety of patients under 2 years old has not been established. For those over 2 years old, the dosage should be precisely adjusted according to body weight, and granules should be pre mixed with food for consumption.

(4) Liver dysfunction

Mild to moderate dosage adjustment is not necessary, and individuals with severe liver function impairment should use it with caution and strengthen monitoring.

(5) Renal insufficiency

Mild to moderate patients do not require dose adjustment, and severe renal insufficiency (creatinine clearance rate<30mL/min) should be used with caution.